This list of U.S.-based National Institutes of Health trials is derived from the NIH's database and includes U.S. interstitial cystitis trials that are currently recruiting participants as well as phase IV U.S. incontinence/overactive bladder trials. This list is current as of March 11, 2011. For more information, view the complete database at http://ClinicalTrials.gov.
Denervating the kidney to ease the pain associated with autosomal dominant polycystic kidney disease shows promising success in early trials.
Robot-assisted radical cystectomy can be performed safely and effectively by urologists who are experienced with robotic surgery.
Does milder interstitial cystitis progress to an inevitable bad end with no apparent option but diversion?
Many providers try to treat VUR on their own. And fewer than half are aware of the use of dextranomer/hyaluronic acid to treat VUR in children.
A detailed diagnostic algorithm and a lowering of the index patient age are among additions to the AUA's updated clinical guideline on the diagnosis and treatment of BPH.
Using tissue samples from primary renal tumors and matching resected or biopsied metastatic deposits, researchers reported new insights into determining which patients may benefit most from such mTOR inhibitors as temsirolimus (Torisel) and everolimus (Afinitor).
A multicenter study comparing aneuploidy rates between concurrent ejaculated and testicular spermatozoa from the same individual reveals lower DNA damage but higher aneuploidy rates among testicular spermatozoa of men with persistently high sperm DNA damage.
With Republicans in control of the House of Representatives, there is some potential good news and bad news for physicians, including urologists, as the drive to slash the federal deficit moves into high gear.
In men with erectile dysfunction due to Peyronie's disease, use of a girth-expanding, length-extending implantable penile prosthesis appears to improve both erectile function and curvature while addressing the frequent problem of real or perceived shortening.
Throughout recent history, periods of economic upheaval and market volatility have led people to assume that life had somehow forever changed and that new economic rules or an expanding government would limit growth.
Physicians don't have the luxury of making bad decisions about purchasing new equipment.
Urologists are expected to spend more money on building a solid infrastructure and expanding technology at a time when many are concerned about practice economics. Fortunately, there are some actions you can take to improve practice finances.
Submit a question for an upcoming Urology Times Q&A.
Newer, more expensive treatment options for prostate cancer were adopted rapidly and widely during 2002 through 2005 without proof of their cost-effectiveness, according to a recent study.
Updated National Comprehensive Cancer Network guidelines call for more rigorous monitoring of men with prostate cancer undergoing active surveillance and include new treatment options for patients with advanced disease.
The Medicare Payment Advisory Commission (MedPAC) has recommended a 1% increase in payments for physician services in 2012 as part of its "Report to the Congress: Medicare Payment Policy."
The AUA, the American Association of Clinical Urologists, and seven other specialty societies have joined forces to support legislation introduced in the Maryland General Assembly to amend the state?s current self-referral law, which the AUA says threatens to seriously restrict patient access to imaging and radiation therapy services.
In a recent letter to the FDA, the American Medical Association called for genetic testing to be conducted under the guidance of a physician, genetic counselor, or other genetics specialist.
High rates of inappropriate antibiotic use persist despite a 15-year national outreach campaign by the Centers for Disease Control and Prevention to educate providers and consumers on the dangers of antibiotic overuse, according to an issue brief from the Center for Healthcare Research & Transformation, Ann Arbor, MI.
Men who take statins may be 60% less likely to be diagnosed with high-grade prostate cancer, according to a study presented at the Prostate Cancer Research Program?s Innovative Minds in Prostate Cancer Today (IMPaCT) conference in Orlando, FL.
When hospitals acquire surgical robotic technology, men in that region are more likely to undergo radical prostatectomy, according to a recent multicenter study.
Microdissection testicular sperm extraction (TESE) can effectively locate and extract viable sperm in more than one-third of adult male childhood cancer survivors who were previously considered sterile due to prior chemotherapy treatment, according to a recent study.
Researchers at the Institute for Regenerative Medicine have used patients? own cells to build tailor-made urethras and successfully replace damaged tissue.
Researchers at the University of Michigan Comprehensive Cancer Center, Ann Arbor, have identified a potential target to treat an aggressive type of prostate cancer.
Men who take nonsteroidal anti-inflammatory drugs three times per day for more than 3 months are 2.4 times more likely to have erectile dysfunction than men who do not take the drugs regularly, say researchers from several California locations of Kaiser Permanente.
More than 21,000 health care providers initiated registration for the Medicare and Medicaid EHR Incentive Programs in January, and four states reported initial Medicaid incentive payments totaling more than $20 million, the Centers for Medicare & Medicaid Services reported.
PSA velocity is a poor predictor of prostate cancer and may lead to many unnecessary biopsies, according to a recent study.
The RANK Ligand inhibitor denosumab (Xgeva) significantly delays skeletal-related events (SREs) in men with prostate cancer and bone metastases, French researchers recently reported.
